<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02368275</url>
  </required_header>
  <id_info>
    <org_study_id>Predictive cohort</org_study_id>
    <nct_id>NCT02368275</nct_id>
  </id_info>
  <brief_title>Genetic, Neurophysiological and Psychological Risk Factors for Neuropathic Pain</brief_title>
  <official_title>Role of Genetic, Neurophysiological and Psychological Factors in the Development of Postsurgical Neuropathic Pain After Breast Surgery for Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Ambroise Paré Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hopital Foch</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Ambroise Paré Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of these cohorts is to detect potential genetic, neurophysiological&#xD;
      psychological and cognitive risk factors for the development of chronic postsurgical pain&#xD;
      including neuropathic pain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This new study will enroll patients undergoing mastectomy or thoracotomy for cancer. They&#xD;
      will be three cohorts :&#xD;
&#xD;
        -  one prospective cohort constituted of women undergoing breast surgery in René Huguenin&#xD;
           Hospital (Saint Cloud) and followed for up to one year after surgery.&#xD;
&#xD;
        -  another cross sectional cohort constituted of patient association (Seintinelle)&#xD;
           including women operated up to 2 years previously from breast surgery.&#xD;
&#xD;
        -  One prospective cohort constituted of women or men undergoing thoracotomy in Foch&#xD;
           hospital (Suresnes) and followed for up to one year after surgery.&#xD;
&#xD;
      The main objectives of these cohorts will be to detect potential genetic, neurophysiological,&#xD;
      psychological and cognitive risk factors for the development of chronic postsurgical&#xD;
      neuropathic pain.&#xD;
&#xD;
      These patients will questioned about demographics, age, sex, body mass index. A large&#xD;
      neuropsychological and psychological battery of tests will be conducted. Sensory function&#xD;
      will assessed using quantitative sensory testing. Biological samples will analyse potential&#xD;
      genetic factors in the development of neuropathic pain after surgery. Conditioned pain&#xD;
      modulation, threshold tracking and quantitative sensory testing will also be assessed in&#xD;
      subgroup of patients.&#xD;
&#xD;
      The prospective cohort will be assessed before surgery then 3, 6 and 12 months after surgery.&#xD;
      The cross sectional cohort will be assessed during one to two visits in hospital.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Actual">September 30, 2020</completion_date>
  <primary_completion_date type="Actual">July 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>neuropathic pain</measure>
    <time_frame>3, 6 and 12 months after surgery in the prospective cohort</time_frame>
    <description>neuropathic pain assessed with the DN4 questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>chronic postsurgical pain</measure>
    <time_frame>3, 6 and 12 months after surgery</time_frame>
    <description>chronic pain questionnaire identification</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">250</enrollment>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>prospective cohort of patients undergoing mastectomy</arm_group_label>
    <description>Prospective cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cross sectional cohort of patients</arm_group_label>
    <description>Cross sectional cohort</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      The samples will use GWAS to detect potential genetic risk factors for neuropathic pain.&#xD;
      These data will be analysed in Oxford laboratory (McCarthy).&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The first group of patients consists of women recruited from René Huguenin Hospital (Saint&#xD;
        Cloud, Ile de France) for mastectomy or lumpectomy to treat breast cancer, with axillary&#xD;
        lymph node dissection in all cases.&#xD;
&#xD;
        The second cohort will consist of women already operared of breast surgery in the last 2&#xD;
        years.&#xD;
&#xD;
        The third cohort will consist of men or women recruited from Foch hospital (Suresnes, Ile&#xD;
        de France) for thoracotomy for cancer.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing surgery for breast cancer or thoracotomy for lung cancer followed&#xD;
             during the course of the study or patients from the French cohort Seintinelle already&#xD;
             operated from breast surgery over the past 2 years.&#xD;
&#xD;
        Exclusion criteria :&#xD;
&#xD;
          -  Patients are not included if they have clinically significant or unstable psychiatric&#xD;
             or somatic conditions (e.g. major depression, psychosis, uncontrolled diabetes&#xD;
             mellitus or hypertension, neurological disorders, immune disease, body mass index &gt;&#xD;
             45), past or present substance abuse or any cognitive deterioration based on past&#xD;
             medical history, semi-structured interview and lack of completion or full&#xD;
             understanding of questionnaires.&#xD;
&#xD;
          -  Bilateral mastectomy (for women undergoing breast surgery)&#xD;
&#xD;
          -  Presence of pain before surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nadine ATTAL, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Principal Investigator</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Foch</name>
      <address>
        <city>Suresnes</city>
        <state>Hauts De Seine</state>
        <zip>92</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Ambroise Paré</name>
      <address>
        <city>Boulogne Billancourt</city>
        <zip>92100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 13, 2015</study_first_submitted>
  <study_first_submitted_qc>February 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2015</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Ambroise Paré Paris</investigator_affiliation>
    <investigator_full_name>Nadine ATTAL</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

